Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Inclusion Criteria: * Histologically confirmed diagnosis of superficial transitional cell carcinoma of the bladder (Ta, T1) * Recurrent superficial bladder cancer refractory to Bacillus Calmette-Guerin (BCG) * No previous intravesical therapy for 6 weeks * No history of prior radiation to the pelvis * Peripheral neuropathy ≤ grade 1 * Eastern Cooperative Oncology Group (ECOG) performance status 0 t0 2 * Adequate hematopoietic and hepatic parameters Exclusion Criteria: * Muscle invasive disease (T2-T4) * Any other malignancy diagnosed within 2 years of study entry (Except basal or squamous cell skin cancers or noninvasive cancer of the cervix) * Participation in any other research protocol involving administration of an investigational agent within 3 months before study entry * History of sensitivity reaction to docetaxel * Prescribed immunosuppressive medications because of a confounding medical condition * Female patients who were pregnant or lactating